Early-Stage R&D In The Spotlight As BMS Patent Expirations Approach
Rupert Vessey Notes Proof-Of-Concept Programs, Partnering Priorities
With the first Revlimid generics launching in 2022, Bristol Myers Squibb’s late-stage assets are key, but earlier programs will help fill the void as Opdivo and Eliquis lose exclusivity later in the decade.
